Skip to main content

Table 2 Patient demographics

From: Sedative effect of remimazolam combined with alfentanil in colonoscopic polypectomy: a prospective, randomized, controlled clinical trial

Characteristics AP Group
(n = 27)
AR1 Group
(n = 28)
AR2 Group
(n = 30)
AR3 Group
(n = 29)
age years 56.00 ± 10.13 54.11 ± 12.08 49.70 ± 8.95 52.24 ± 9.80
male/female 17/10 20/8 23/7 19/10
BMI, kg/m2 22.28 ± 1.61 22.20 ± 1.71 22.43 ± 1.77 22.40 ± 1.67
ASA classification
  I 20 (74.1%) 23 (82.1%) 24 (80.0%) 23 (79.3%)
  II 7 (25.9%) 5 (17.9%) 6 (20.0%) 6 (20.7%)
  1. Note: Data are presented as mean ± SD and number (percentage)
  2. Abbreviations: AP Alfentanil and propofol, AR1 Alfentanil and remimazolam (0.1 mg/kg), AR2 Alfentanil and remimazolam (0.15 mg/kg), AR3 Alfentanil and remimazolam (0.2 mg/kg), ASA American Society of Anesthesiologists physiological status, BMI Body mass index